| Celiac disease (12) |  |
| Colitis (15) | |
| Constipation (3) | |
| Crohn's disease (11) | |
| Diarrhea (28) | |
| Gastroenteritis (15) | |
| Gastrointestinal disease (4) | |
| Hernia (3) | |
| Irritable bowel syndrome (10) | |
| Liver diseases (92) | |
| Nausea (13) | |
| Pancreatitis (10) | |
| Celiac disease (12) | |
| Colitis (15) | |
| Constipation (3) | |
| Crohn's disease (11) | |
| Diarrhea (28) | |
| Gastroenteritis (15) | |
| Gastrointestinal disease (4) | |
| Hernia (3) | |
| Irritable bowel syndrome (10) | |
| Liver diseases (92) | |
| Nausea (13) | |
| Pancreatitis (10) | |
are expected to accelerate the development of targeted therapies for inflammatory gastrointestinal diseases. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are disorders of unknown etiology that are characterized often by abdominal pain, diarrhea, bloody stool, fever,
which has frequently been observed in autistic children, its association with gastrointestinal diseases --which often accompany autistic disorders
It quickly became clear to the investigators that Strain 115 could produce a potent antibiotic that targets a large number of medically relevant bacteria including those that cause staph infections strep throat and severe gastrointestinal diseases.
would complement Shire existing stable of drugs for gastrointestinal diseases.""The acquisition of NPS Pharma is a significant step in advancing Shire's strategy to become a leading biotechnology company, Shire CEO Flemming Ornskov, M d,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011